Mereo BioPharma Group plc (MREO) Financials

MREO Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 40.6 million 6.6 million
Dec. 31, 2025 45.9 million 5.0 million
Sept. 30, 2025 53.6 million 7.0 million
June 30, 2025 62.6 million 8.5 million

MREO Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -4.3 million 1.6 million
Dec. 31, 2025 -7.7 million 1.5 million
Sept. 30, 2025 -7.3 million 1.7 million
June 30, 2025 -7.7 million 2.1 million

MREO Net Income

No data available :(

MREO Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 36.2 million - -
Dec. 31, 2025 41.0 million - 202000
Sept. 30, 2025 48.7 million - 397000
June 30, 2025 56.1 million - 601000

MREO Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 160.4 million
Dec. 31, 2025 159.4 million
Sept. 30, 2025 160.0 million
June 30, 2025 159.9 million

MREO Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 4.7 million 4.0 million -
Dec. 31, 2025 1521 4.2 million 4.2 million -
Sept. 30, 2025 - 3.8 million 6.0 million -
June 30, 2025 - 5.4 million 5.5 million -

MREO Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 304488
Dec. 31, 2025 - 1000
Sept. 30, 2025 - 1000
June 30, 2025 500000 132000

MREO

Price: $0.31

52 week price:
0.20
3.05

Earnings Per Share: -0.20 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 278100

Market Capitalization: 48.2 million

Links: